JENTADUETO

Clinical safety rating: caution

Comprehensive clinical and safety monograph for JENTADUETO (JENTADUETO).

How it works

Jentadueto is a combination of linagliptin and metformin. Linagliptin inhibits DPP-4, increasing incretin levels (GLP-1, GIP) and enhancing glucose-dependent insulin secretion while suppressing glucagon. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.

What the body does with it

Metabolism	Linagliptin: minimal metabolism, primarily excreted unchanged via bile and gut (enterohepatic circulation). Metformin: not metabolized, excreted unchanged by kidneys.
Excretion	Renal: linagliptin ~5% unchanged; metformin ~90% unchanged. Fecal: linagliptin ~80% (mostly unchanged). Biliary: minimal.
Half-life	Linagliptin: terminal t1/2 ~12 hours (long binding to DPP-4). Metformin: terminal t1/2 ~6.2 hours (renal impairment prolongs).
Protein binding	Linagliptin: ~75-89% (saturable binding to DPP-4). Metformin: negligible (<5% bound to plasma proteins).
Volume of Distribution	Linagliptin: Vd ~1.0 L/kg (extensive tissue distribution). Metformin: Vd ~0.6-1.1 L/kg (confined to blood and peripheral tissues).
Bioavailability	Linagliptin: ~30% oral. Metformin: ~50-60% oral (fasted).
Onset of Action	Linagliptin: DPP-4 inhibition within 1-2 hours. Metformin: glucose-lowering effect within 2-3 hours (oral).
Duration of Action	Linagliptin: ~24 hours (once-daily dosing). Metformin: up to 24 hours (extended-release component).

Classification & Brands

Dosing & administration

Administered orally twice daily with meals. Initial dose: one tablet JENTADUETO 5 mg/500 mg or 5 mg/1000 mg; subsequent titration based on glycemic response. Maximum daily dose: linagliptin 5 mg, metformin 2000 mg.

Dosage form	TABLET
Renal impairment	Contraindicated if eGFR <30 mL/min/1.73 m². For eGFR 30-45 mL/min/1.73 m²: maximum metformin dose 1000 mg/day (e.g., JENTADUETO 5 mg/500 mg twice daily or 5 mg/1000 mg once daily). Assess renal function before initiation and at least annually. Discontinue if eGFR falls persistently below 30 mL/min/1.73 m².
Liver impairment	Avoid use in patients with hepatic impairment (Child-Pugh class A, B, or C) due to metformin component and risk of lactic acidosis. No specific dosing recommendations available.
Pediatric use	Safety and efficacy not established in pediatric patients under 18 years. Not recommended.
Geriatric use	Initiate at lower doses (e.g., JENTADUETO 5 mg/500 mg twice daily) with gradual titration to minimize gastrointestinal side effects. Monitor renal function closely, as elderly are more susceptible to decreased eGFR and lactic acidosis.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for JENTADUETO (JENTADUETO).

Breastfeeding	Metformin is excreted into human milk with M/P ratio approximately 0.2–1.0. Linagliptin is likely excreted. Insufficient data; use caution. Consider risk of hypoglycemia and lactic acidosis in nursing infants.
Teratogenic Risk	Insufficient human data; animal studies show fetal toxicity at maternally toxic doses. Use in pregnancy only if benefit outweighs risk. Avoid in second and third trimesters due to potential for metformin-associated lactic acidosis in neonates.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Lactic acidosis associated with metformin; avoid use in patients with renal impairment, acute congestive heart failure, etc.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Severe renal impairment (eGFR < 30 mL/min/1.73 m²)","Acute or chronic metabolic acidosis (including diabetic ketoacidosis)","History of serious hypersensitivity reaction to linagliptin or metformin"]

Clinical Precautions

Precautions

["Lactic acidosis (metformin component)","Pancreatitis (linagliptin component)","Hypoglycemia when used with insulin secretagogues or insulin","Renal impairment (assess before and during therapy)","Vitamin B12 deficiency (long-term metformin use)"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

JENTADUETO

Clinical safety rating: caution

Comprehensive clinical and safety monograph for JENTADUETO (JENTADUETO).

How it works

What the body does with it

Metabolism	Linagliptin: minimal metabolism, primarily excreted unchanged via bile and gut (enterohepatic circulation). Metformin: not metabolized, excreted unchanged by kidneys.
Excretion	Renal: linagliptin ~5% unchanged; metformin ~90% unchanged. Fecal: linagliptin ~80% (mostly unchanged). Biliary: minimal.
Half-life	Linagliptin: terminal t1/2 ~12 hours (long binding to DPP-4). Metformin: terminal t1/2 ~6.2 hours (renal impairment prolongs).
Protein binding	Linagliptin: ~75-89% (saturable binding to DPP-4). Metformin: negligible (<5% bound to plasma proteins).
Volume of Distribution	Linagliptin: Vd ~1.0 L/kg (extensive tissue distribution). Metformin: Vd ~0.6-1.1 L/kg (confined to blood and peripheral tissues).
Bioavailability	Linagliptin: ~30% oral. Metformin: ~50-60% oral (fasted).
Onset of Action	Linagliptin: DPP-4 inhibition within 1-2 hours. Metformin: glucose-lowering effect within 2-3 hours (oral).
Duration of Action	Linagliptin: ~24 hours (once-daily dosing). Metformin: up to 24 hours (extended-release component).

Classification & Brands

Dosing & administration

Dosage form	TABLET
Renal impairment	Contraindicated if eGFR <30 mL/min/1.73 m². For eGFR 30-45 mL/min/1.73 m²: maximum metformin dose 1000 mg/day (e.g., JENTADUETO 5 mg/500 mg twice daily or 5 mg/1000 mg once daily). Assess renal function before initiation and at least annually. Discontinue if eGFR falls persistently below 30 mL/min/1.73 m².
Liver impairment	Avoid use in patients with hepatic impairment (Child-Pugh class A, B, or C) due to metformin component and risk of lactic acidosis. No specific dosing recommendations available.
Pediatric use	Safety and efficacy not established in pediatric patients under 18 years. Not recommended.
Geriatric use	Initiate at lower doses (e.g., JENTADUETO 5 mg/500 mg twice daily) with gradual titration to minimize gastrointestinal side effects. Monitor renal function closely, as elderly are more susceptible to decreased eGFR and lactic acidosis.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for JENTADUETO (JENTADUETO).

Breastfeeding	Metformin is excreted into human milk with M/P ratio approximately 0.2–1.0. Linagliptin is likely excreted. Insufficient data; use caution. Consider risk of hypoglycemia and lactic acidosis in nursing infants.
Teratogenic Risk	Insufficient human data; animal studies show fetal toxicity at maternally toxic doses. Use in pregnancy only if benefit outweighs risk. Avoid in second and third trimesters due to potential for metformin-associated lactic acidosis in neonates.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Lactic acidosis associated with metformin; avoid use in patients with renal impairment, acute congestive heart failure, etc.